Electronic monitoring of compliance to lipid-lowering therapy in clinical practice

Journal of Clinical Pharmacology

Volumn 39, Issue 4, 1999, Pages 402-409

  Schwed, Ariane ^a   Fallab, Claire Lise ^a   Burnier, Michel ^a,b   Waeber, Bernard ^b   Kappenberger, Lukas ^b   Burnand, Bernard ^d   Darioli, Roger ^a,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG MONITORING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INTERMETHOD COMPARISON; MALE; MONITOR; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ANXIETY; CHOLESTEROL, LDL; ELECTRONICS, MEDICAL; FATIGUE; FATTY ACIDS, MONOUNSATURATED; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; LIPIDS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 0032922907     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007976     Document Type: Article

References (38)

1. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
2. Frick H, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
3. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
4. Byington RP, Wouter-Jukema J, Salonen JT, Pitt B, Bruschke AV, Hoen H, et al: Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995;92:2419-2425.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
6. Mäenpää H, Manninen V, Heinonen OP: Compliance with medication in the Helsinki Heart Study. Eur J Clin Pharmacol 1992;42:15-19.
7. Gotto AM Jr: Therapeutic intervention for hypercholesterolemia. Clin Cardiol 1992;15(Suppl. 3):18-21.
8. Coronary Drug Project Research Group: Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980;303:1038-1041.
9. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
10. Stewart M: The validity of an interview to assess a patient drugs taking. Am J Prev Med 1987;3:95-100.
11. Rudd P, Byyny RL, Zachary V, LoVerde ME, Mitchell WD, Titus C, et al: Pill count measures of compliance in a drug trial: variability and suitability. Am J Hypertens 1988;1:309-312.
12. Pullar T, Kumar S, Tindall H, Feely M: Time to stop counting the tablets? Clin Phamacol Ther 1989;46:163-168.
13. Mäenpää H, Manninen V, Heinonen O: Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. Eur Heart J 1987;8(Suppl. 1):39-43.
14. Guerrero D, Rudd P, Bryant-Kosling C, Middleton BF: Antihypertensive medication-taking: investigation of a simple regimen. Am J Hypertens 1993;6:586-592.
15. Kruse W, Rampmaier J, Ullrich G, Weber E: Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Intern J Clin Pharmacol and Ther 1994;32:452-457.
16. Detry J-MR, Block P, de Baker G, Degaute J-P, Six R: The Belgian Collaborative Study Group: patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. Eur J Clin Pharmacol 1995;47:477-481.
17. Mallion JM, Dutrey-Dupagne C, Vaur L, Genes N, Renault M, Elkik F, et al: Benefits of electronic pillboxes in evaluating treatment compliance of patients with mild to moderate hypertension. J Hypertens 1996;14:137-144.
18. Kass MA, Meltzer DW, Gordon M, Cooper D, Goldberg J: Compliance with topical pilocarpine treatment. Am J Ophtalmol 1986;101:515-523.
19. Olivieri NF, Matsui D, Hermann C, Koren G: Compliance assessed by the Medication Event Monitoring System. Arch of Disease in Childhood 1991;66:1399-1402.
20. Kruse W, Weber E: Dynamics of drug regimen compliance: its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 1990;38:561-565.
21. Waterhouse DM, Calzone KA, Mele C, Brenner DE: Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993;11:1189-1197.
22. Kruse W, Schlierf G, Weber E: Dynamically compliance monitoring: its utility for the interpretation of drug trials. Eur J Clin Pharmacol 1989;36(Suppl. A):289.
23. Kruse W, Nikolaus T, Rampmaier J, Weber E, Schlierf G: Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. Eur J Clin Pharmacol 1993;45:211-215.
24. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
25. Leitersdorf E, Eisenberg S, Eliav O, Berkman N, Dann EJ, Landsberger D, et al: Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolemia. Eur J Clin Pharmacol 1993;45:513-518.
26. Zavoral JH, Haggerty BJ, Winick, AG, Bergmann SD, on behalf of the Fluent Study Group: Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor. Am J Cardiol 1995;76(Suppl.):37A-40A.
27. Insull W Jr, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L, et al: Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med 1994;154:2449-2455.
28. Ose L, Scott R, and the Simvastatin-Fluvastatin Study Group: Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolemia. Clin Drug Invest 1995;10:127-138.
29. Jacotot B, Benghozi R, Pfister P, Holmes D, on behalf of the French Fluvastatin Study Group: Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. Am J Cardiol 1995;76(Suppl.):54A-56A.
30. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al: Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-1131.
31. Insull W, Troendle A, Silvers A, Dunne CW: The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317-325.
32. Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D: Improved compliance measures: application in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 1990;48:676-685.
33. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL: How often is medication taken as prescribed? JAMA 1989;261:3273-3277.
34. Cramer JA, Scheyer RD, Mattson RH: Compliance declines between clinic visits. Arch Intern Med 1990;150:1509-1510.
35. Pullar T: Compliance with drug therapy. Br J Clin Pharmac 1991;32:535-539.
36. Kruse W: Patient compliance with drug treatment: new perspectives on an old problem. Clin Investig 1992;70:163-166.
37. Matsui DM, Hermann C, Klein J, Berkovitch M, Olivieri N, Koren, G, et al: Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol 1994;34:944-949.
38. Fallab-Stubi CL, Zellweger JP, Sauty A, Uldry Ch, Iorillo D, Burnier M: Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis. Int J Tuberc Lung Dis 1998;2:525-530.